General Incorporated Association Pharma Valley Project Supporting Organization

Kabushiki Kaisha Yakult Honsha

Pharmadesign, Inc.

Shizuoka Prefecture

Kumamoto Health Science University

Canbas Co., Ltd.

Yaizu Suisankagaku Industry Co., Ltd.

Pharma IP General Incorporated Association

Naohisa Ogo

Akira Asai

Osamu Takahashi

Yasuto Akiyama

Daisuke Muraoka

Kenji Matsuno

Tadashi Ashizawa

Tadashi Okawara

Hiroshi Shiku

Takumi Kawabe

Takuji Sato

Naozumi Harada

Yoshiaki Masuda

Takane Yokotagawa

Osamu Takikawa

Mai Ohba

Takayuki Ando

Ayumu Muroya

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, Rand Rrepresent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and Rand Rare the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, Rrepresents, for example, —C(═NH)—HN, and Rrepresents, for example, a substituted or unsubstituted aryl group].

IDO/TDO inhibitor

To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.

Agent for overcoming immunosuppression and use thereof

Provided are: a composition having an excellent anti-norovirus effect; use of a theaflavin compound for the preparation of the composition; and a method for preventing infection with a norovirus using a theaflavin compound. A theaflavin compound is used as an active ingredient for preventing infection with a norovirus. The theaflavin compound is preferably used together with an alcohol. The theaflavin compound is preferably one or more members selected from the group consisting of theaflavin, theaflavin-3-O-gallate, theaflavin-3'-O-gallate and theaflavin-3,3&#x2032;-O-digallate that are derived from tea components.

Anti-norovirus composition and utilization thereof

Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; Rrepresents a hydrogen atom or the like; and &#x2014;X&#x2014;Y represents a diaryl group such as a biphenyl group). 

1,3,4-Oxadiazole-2-carboxamide compound

The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR; and Rto Rand Reach represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like), or a pharmacologically acceptable salt thereof. 

STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient

Growing community of inventors

Shizuoka, Japan

Naohisa Ogo